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Abstract
Background: Data on surveillance for pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals (HRIs) with
‘‘familial pancreatic cancer’’ (FPC) and specific syndromes are limited and heterogeneous.
Objective: We conducted a systematic review and meta-analysis of PDAC surveillance studies in HRIs.
Methods: Prevalence of solid/cystic pancreatic lesions and of lesions considered a successful target of surveillance (proven
resectable PDAC and high-grade precursors) was pooled across studies. The rate of lesions diagnosed by endoscopic
ultrasonography (EUS)/magnetic resonance imaging (MRI) and across different HRI groups was calculated.
Results: Sixteen studies incorporating 1588 HRIs were included. The pooled prevalence of pancreatic solid and cystic lesions
was 5.8% and 20.2%, respectively. The pooled prevalence of patients with lesions considered a successful target of sur-
veillance was 3.3%, being similar to EUS or MRI and varying across subgroups, being 3% in FPC, 4% in hereditary
pancreatitis, 5% in familial melanoma, 6.3% in hereditary breast/ovarian cancer, and 12.2% in Peutz-Jeghers syndrome.
The pooled estimated rate of lesions considered a successful target of surveillance during follow-up was 5/1000 person-
years.
Conclusion: Surveillance programs identify successful target lesions in 3.3% of HRIs with a similar yield of EUS and MRI and
an annual risk of 0.5%. A higher rate of target lesions was reported in HRIs with specific DNA mutations.
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Key summary
1. Summarize the established knowledge on this subject.
. Surveillance of pancreatic cancer is advised in individuals with ‘‘familial pancreatic cancer’’ (FPC) and
speciﬁc genetic syndromes.
. No evidence-based consensus is available on the imaging test preferred between magnetic resonance
imaging (MRI) and endoscopic ultrasonography (EUS).
. Whether surveillance protocols should be diﬀerent in diﬀerent high-risk individual (HRI) subgroups is
unknown.
2. What are the signiﬁcant and/or new ﬁndings of this study?
. The rate of resected lesions considered a successful target of surveillance during pancreatic cancer sur-
veillance programs in HRIs is 3.3% or 0.5% per year.
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. There are no diﬀerences between EUS and MRI in diagnosing a ‘‘successful’’ target of screening.
. The rate of successful target lesions in FPC is lower compared to speciﬁc genetic syndromes, thus sur-
veillance programs might need to be individualized accordingly.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an
increasing cause of cancer-related death, partially
because of delayed diagnosis.1,2 While precursor
lesions, such as intraductal papillary mucinous neo-
plasms (IPMNs), can be detected at early stages,
whether this is possible for pancreatic intraepithelial
neoplasia (PanINs)3 is a matter of debate. At any
rate, general population screening is not advised as
the overall lifetime PDAC risk is relatively low.
However, since a hereditary component accounts for
5% to 10% of cases,3 surveillance is advised for high-
risk individuals (HRIs). The International Cancer of
the Pancreas Screening (CAPS) Consortium4 deﬁned
individuals with ‘‘familial pancreatic cancer’’ (FPC)
or with hereditary syndromes of which PDAC is
one phenotypic manifestation as HRIs. The FPC
deﬁnition is not fully established, but an individ-
ual can be considered at high risk if two blood rela-
tives are aﬀected by PDAC, of whom at least one is
a ﬁrst-degree relative (FDR). Regarding deﬁned
genetic syndromes, surveillance is indicated for all
Peutz-Jeghers syndrome (PJS) patients regardless of
family history. Furthermore, p16 (familial atypical mul-
tiple-mole melanoma syndrome, FAMMM), breast
cancer type 2 susceptibility gene (BRCA2), partner
and localizer of BRCA2 (PALB), and mismatch
repair gene (hereditary nonpolyposis colorectal
cancer, HNPCC) mutation carriers with one FDR or
two other family members with PDAC should undergo
surveillance.5
The ultimate goal of surveillance is to detect and
surgically treat noninvasive precursor lesions, such as
advanced PanINs or IPMNs with high-grade dysplasia,
or early-stage PDAC, that are considered successful
targets of surveillance according to the CAPS
Consortium.4 Data on the eﬃcacy of such surveillance
programs in HRIs in terms of identiﬁcation of the
above-mentioned lesions are limited and heteroge-
neous, thus HRI surveillance is generally performed
in the setting of research protocols.
Both magnetic resonance imaging (MRI) and endo-
scopic ultrasonography (EUS) are employed as ﬁrst-
line modalities for HRI surveillance, but no imaging
test has gained evidence-based consensus.6,7
Furthermore, the results of screening might diﬀer in
terms of detected lesions in each HRI subgroup. As
an example, patients with FAMMM were reported to
develop more solid lesions while FPC individuals more
cystic ones.8,9
This systematic review and meta-analysis is therefore
aimed to assess in HRIs (a) the prevalence of solid and
cystic lesions and of lesions considered a successful
target of surveillance, (b) the prevalence of lesions diag-
nosed by EUS and/or MRI, and (c) the prevalence of
lesions considered a successful target of the surveillance
in diﬀerent HRI subgroups.
Materials and methods
Search strategy
A PubMed and Scopus databases search (see
Appendix 1) was run until June 2017. Duplicates were
removed. The methodology was developed from the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement.10
The titles of all identiﬁed articles were assessed for
their relevance, and abstracts and/or full texts of poten-
tially relevant papers screened and evaluated. A manual
search of all relevant articles and references was con-
ducted to identify further relevant studies.
Inclusion and exclusion criteria
Inclusion criteria were English language, patients
belonging to FPC families and/or with other speciﬁc
high-risk syndromes or germline mutation carriers,
and surveillance carried out with MRI and/or EUS,
with the prevalence and type of diagnosed pancreatic
lesions (solid and/or cystic) being reported. In the case
of duplicate publications, the most recent or most
informative was included. Two independent reviewers
(MS and GZ) carried out study identiﬁcation and selec-
tion and discussed disagreements with a third reviewer
(GC). Excluded studies and reasons for exclusion were
recorded.
Data extraction and quality assessment
Two reviewers (MS and GZ) independently extracted
data from each study into aMicrosoft Excel spreadsheet
(XP Professional Edition; Microsoft Corp, Redmond,
WA, USA). Disagreements were resolved by consulting
a third reviewer (GC). Study year, design and location,
number of screened individuals, and type of high-risk
subgroups, and of imaging, follow-up duration,
number, and type of diagnosed lesions, and of patients
with an indication for surgery and with an identiﬁed
lesion considered to be a success of the surveillance or
diagnosed with advanced/metastatic PDAC were
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recorded. A summary table of the relevant studies listing
the population characteristics and outcomes was devel-
oped. The quality of the studies was evaluated independ-
ently by two reviewers (MS and GC) using the
Newcastle-Ottawa Scale11 with a dedicated quality
appraisal tool including seven items. Studies with a
score 7 were considered of high quality.
Data analysis
We examined (a) the pooled prevalence rate of all solid
or cystic lesions, and (b) the pooled prevalence of
lesions being considered a successful target of surveil-
lance as deﬁned by gold-standard pathology after
surgery. Lesions considered as successful targets of sur-
veillance were: PanIN3 (or high-grade PanIN if not
speciﬁed), IPMNs with high-grade dysplasia or main
duct (MD)/mixed-type IPMN, and any resectable
PDAC with R0 pathology. This deﬁnition is adapted
from the CAPS one, as some of the papers did not
provide enough information for detailed grouping; the
pooled prevalence rate of advanced IPMNs and
PanIN3 lesions was also calculated, considering them
as ‘‘premalignant’’ target lesions; (c) the pooled preva-
lence rate of advanced/metastatic PDAC, not amenable
to R0 resection; (d) the pooled prevalence of the above-
mentioned lesions detected either by EUS or by MRI;
and (e) the pooled prevalence of successful target
lesions in each speciﬁc HRI group.
Data were combined to generate a pooled prevalence
rate. To better reﬂect the incidence of detected lesions
over time, we also calculated the incidence rates of
lesions being a successful target of surveillance by divid-
ing the total number of events by the total number of
person-years (pyrs) of follow-up. If these latter data
were not provided in a study, it was estimated by multi-
plying the number of patients who underwent surveil-
lance by the reported mean follow-up time. The
corresponding 95% conﬁdence intervals (CIs) were cal-
culated using exact methods and assuming a Poisson
distribution. When the number of events was 0, a con-
tinuity correction of 0.5 was used for the purpose of
calculation, as previously reported.12
A meta-analysis was performed using the software
package Comprehensive Meta-Analysis (Biostat,
Englewood, NJ, USA) by using a random-eﬀects
model.13 In addition to within-study variance, the
random-eﬀects model considers heterogeneity among
studies and gives more conservative estimates. The
quantity of heterogeneity was assessed by means of
the I2 value.14 The I2 describes the percentage of total
variation across studies that is caused by heterogeneity
and not by chance. Publication bias was assessed using
the Begg and Mazumdar test. A p value< 0.05 was
accepted as statistically signiEcant. We developed the
following a priori hypotheses that would explain het-
erogeneity and planned sensitivity analyses for (a) area
of origin (i.e., United States (US)/Canada or Europe)
and (b) quality of the study (quality score >7 or 7).
Results
Search results and study selection and
characteristics
The study selection process is summarized in Figure 1.
Sixteen studies met the eligibility criteria and were
included for qualitative analysis and quantitative
synthesis. One of them15 is a multicenter study whose
ﬁndings were already reported in three previous single-
center studies.9,16,17 As the population of this latter
study was larger and results regarding the diﬀerent
HRIs subgroups more detailed, we used this manu-
script for the analysis of pooled prevalence of overall
lesions. However, as this more recent paper does not
report the exact number of cystic/solid lesions diag-
nosed by either EUS or MRI, we used data from
the older studies for the analyses on the role of MRI
and EUS.
Table 1 summarizes the characteristics of the 16
included studies. Two papers reported only the ﬁrst
surveillance round18,19 while two other studies did not
report the exact follow-up period.20,21 The mean
follow-up in studies reporting> one surveillance
round2,6,7,15,22–26 was 32.4 months, and the total
number of enrolled HRIs 1588. Considering the 1572
individuals for whom this information was available,
the largest group of screened individuals was FPC
(1043, 66.3% of total) followed by FAMMM (243,
15.4%) and hereditary breast and ovarian cancer
(HBOC) syndrome individuals or BRCA1/2 mutation
carriers (140, 8.9%). Some studies also enrolled indi-
viduals who did not meet the criteria to be designated
as ‘‘HRI’’ according to the CAPS consortium.2,7,18–20
There were four patients with Li-Fraumeni syn-
drome,9,22 ﬁve with only one aﬀected family
member,25 nine with a family member with early-
onset PDAC,24 and six with >1 relative with non-
pancreatic cancers;2 all together these people accounted
for 1.6% of the investigated individuals. Two studies
enrolled patients with a very low risk of developing
pancreatic cancer based on family history19,21 and
those individuals therefore were not included in the
analysis. Only four4,7,20,25 of the 16 studies were
scored as of ‘‘high quality.’’
Prevalence of solid pancreatic lesions in HRIs
A total of 79 pancreatic solid lesions were detected,
with a pooled prevalence of 5.8% (95% CI 3%–9%;
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I2¼ 77.5%) (Figure 2). No publication bias was found
(Begg and Mazudmar Kendall’s tau¼ –0.21; p¼ 0.27).
When considering only the studies conducted in the
USA or Canada, the pooled estimate prevalence was
3.8% (95% CI 2%–8%; I2¼ 68.8%), compared to
6.8% with similar heterogeneity (95% CI 4%–12%;
I2¼ 61.2%) in the studies from Europe. The pooled
prevalence of solid lesions in studies of high qual-
ity4,7,20,25 was 2.8% (95% CI 1%–6%) compared to
7.7% (95% CI 5%–12%) in the 11 studies of lower
quality,2,9,16–19,21–24,26 with lower heterogeneity
(I2¼ 38.2% vs I2¼ 72.3%) in high-quality studies.
Prevalence of cystic pancreatic lesions
A total of 340 pancreatic cystic lesions were detected,
with a pooled prevalence of 20.2% (95% CI 14%–28%;
I2¼ 88.9%) (Figure 2). Information on prevalence of
pancreatic cystic lesions was not provided in one
study.26 No publication bias was found (Begg
and Mazudmar Kendall’s tau¼ –0.34; p¼ 0.09). The
pooled prevalence of cystic lesions was 23.4% (95%
CI 16%–34%; I2¼ 84.1%) in the studies conducted in
the USA and Canada, and 18.4% (95% CI 8%–37%;
I2¼ 92.1%) in the studies conducted in Europe. In stu-
dies with a high-quality score, the pooled prevalence of
cystic lesions was 33.6% (95% CI 21%–49%;
I2¼ 90.3%), being higher than the 15.4% (95% CI
10%–24%) of studies with a low-quality score, yet
with similar heterogeneity (I2¼ 83.7%).
Prevalence of successful target lesions
of surveillance
Of 1588 screened HRIs, 95 were considered to have an
indication for surgery (pooled prevalence 6.8%; 95%
CI 4%–11%; I2¼ 81%). However, the pooled preva-
lence of individuals for whom surveillance identiﬁed a
lesion considered a successful target of surveillance was
3.3% (95% CI 2%–5%; I2¼ 40.5%) (Figure 3). In
high-quality studies, this pooled prevalence was 2.9%
(95% CI 1%–8%; I2¼ 69.2%), being 3.4% (95% CI
2%–5%; I2¼ 23.4%) in studies of lower quality. In
the sensitivity analysis by country of origin, the
pooled prevalence was 2.7% (95% CI 1%–5%;
I2¼ 43.3%) for studies conducted in the USA or
Canada and 4.1% (95% CI 2%–8%; I2¼ 52.2%) for
studies conducted in Europe. No publication bias was
found (Begg and Mazudmar Kendall’s tau¼ –0.16;
p¼ 0.45). Furthermore, when we repeated this analysis
excluding individuals who were not at high risk accord-
ing to the guidelines,2,7,18–20 the pooled prevalence was
3.4% (95% CI 2%–5%; I2¼ 44.7%). As the ideal target
of the surveillance programs should be the diagnosis of
‘‘premalignant’’ lesions, the pooled prevalence rate of
advanced IPMNs and PanIN3 lesions was also
903 identified through database
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of assessment of studies identified in
the preset systematic review.
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calculated, and resulted in 1.6% (95% CI 1%–2%;
I2¼ 0%) (see Supplementary Figure 1).
In detail, 26 (1.6%) patients were diagnosed with a
resectable PDAC, 11 (0.7%) with branch duct (BD)-
IPMNs with high-grade dysplasia or an MD-IPMN,
and four (0.3%) with advanced PanINs. Six individuals
were diagnosed with pancreatic neuroendocrine neo-
plasms (pNENs).2,6,15,24 Four of them were resected
and all but one2 had a diameter <15mm. Type and
number of histologically conﬁrmed lesions, including
those successfully operated on, are summarized in
Supplementary Table 1. The pooled estimate rate of
lesions considered a successful target of surveillance
was calculated for 11 studies in which follow-up
length was reported, and resulted in 0.005/pyrs (95%
CI 0.001%–0.005%; I2¼ 56%), equal to 5/1000 pyrs
(Figure 4).
Prevalence of advanced/metastatic pancreatic
adenocarcinoma
During the surveillance programs, nine advanced/meta-
static adenocarcinoma were diagnosed. Six metastatic
PDAC were diagnosed and histologically conﬁrmed by
percutaneous or EUS-guided ﬁne needle aspir-
ation;2,9,19,23 the other three underwent surgical resec-
tion but histology showed a positive resection
margin.9,15 The pooled prevalence of HRIs for which
surveillance identiﬁed advanced PDAC was 1.0% (95%
CI 1%–2%), without heterogeneity (I2¼ 0%).
Prevalence of pancreatic lesions diagnosed
either by EUS or by MRI
Ten studies employed EUS6,7,16–19,22–24,26 and nine
MRI.2,6,7,9,16,19–21,25 The pooled prevalence of solid
lesions was higher in studies employing EUS (5.2%,
95% CI 3%–9%; I2¼ 60.6%) compared with those
using MRI (4.1%, 95% CI 2%–9%; I2¼ 83%)
(Figure 5). The pooled prevalence of cystic lesions
was instead 22.4% (95% CI 15%–32%; I2¼ 89.3%)
with MRI and 16.6% (95% CI 10%–27%; 85.7%)
with EUS in the eight studies providing this informa-
tion, which was lacking in two studies.17,26 The pooled
prevalence of pancreatic lesions considered a successful
target of surveillance was 2.9% with EUS (95% CI
2%–5%; I2¼ 27.4%) and 2.5% with MRI (95% CI
1%–5%; I2¼ 51.7%) (see Figure 5).
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Figure 2. Forest plot showing the pooled prevalence of pancreatic solid lesions (panel (a), on the left) diagnosed in high-risk individuals
in all the 14 included studies and of the pooled prevalence of cystic lesions (panel (b), on the right) diagnosed in high-risk individuals in
the 13 studies reporting this information. Random-effects model demonstrating a pooled prevalence of 5.8% (95% confidence interval (CI)
3%–8%) with moderate heterogeneity (I2¼ 77.5%) for solid lesions and a pooled prevalence of 20.2% (95% CI 14%–29%) with
considerable heterogeneity (I2¼ 88.9%) for cystic ones.
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Figure 3. Forest plot showing the overall pooled prevalence of
successful target lesions of the surveillance that is equal to 3.3%
(95% confidence interval (CI) 2%–5%), with moderate heterogen-
eity (I2¼ 40.5%).
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Prevalence of lesions considered a successful
target of surveillance in different HRI subgroups
The pooled prevalence of lesions considered a success-
ful target of surveillance was 3% (95% CI 2%–5%;
I2¼ 22.2%) in FPC individuals. In people with a
speciﬁc genetic syndrome it was 4% in HP (95% CI
1%–14%), 5% for FAMMM (95% CI 3%–9%),
6.3% in HBOC or BRCA1/2, PALB2 mutation carriers
(95% CI 3%–14%), and 12.2% in PJS (95% CI 4%–
32%), without heterogeneity (I2¼ 0%) in all these
subgroups except for people with HP (I2¼ 12.2%)
(Figure 6). We also analyzed the pooled prevalence
rate of histologically conﬁrmed solid lesions diagnosed
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Figure 5. Summary of the pooled prevalence of pancreatic lesions (solid, cystic and successful target lesions of the surveillance)
diagnosed either by endoscopic ultrasonography (EUS) or magnetic resonance imaging (MRI). CI: confidence interval.
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Figure 4. Forest plot showing the pooled estimate rate of successful target lesions of the surveillance in the 11 studies that reported the
follow-up length. The pooled estimate rate resulted of 5/1000 person years with moderate heterogeneity (I2¼ 56%).
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at the baseline examination in each subgroup. These
data were available for all studies but one.21 The
pooled rate of solid lesions at baseline resulted respect-
ively in: 1.6% (95% CI 1%–3%; I2¼ 0%) in FPC,
5.8% (95% CI 2%–14%; I2¼ 0.8%) in HBOC or
BRCA1/2 mutation carriers, 4.6% (95% CI 2%–12%;
I2¼ 35%) in FAMM, 12% (95% CI 4%–32%; I2¼
0%) in PJS, and 7.2% (95% CI 1%–30%; I2¼ 0.8%)
in HP. The number of pancreatic cancer cases and the
relative proportion of unresectable/metastatic cases
were respectively 12 (25% metastatic) in FPC,
15 (20% metastatic) in FAMMM, four (25% meta-
static) in HBOC, and one (0% metastatic) in HP. No
PDAC cases were diagnosed in PJS patients.
Discussion
As data on the prevalence of lesions diagnosed during
surveillance programs in individuals at high risk of
PDAC are scanty and heterogeneous, we conducted a
meta-analysis to estimate the pooled prevalence of solid
and/or cystic lesions, and more important, whether
detected lesions could be considered a successful
target of surveillance. We also calculated the pooled
estimated rate of detected lesions during the course of
subsequent surveillance rounds, the prevalence of
lesions diagnosed by either EUS or MRI, and the
diﬀerential prevalence of lesions among the various
HRI subgroups.
Data from 1588 enrolled HRIs were included. The
pooled prevalence of solid and cystic lesions in these
individuals was 5.8% and 20.2%, respectively
(Figure 2). The pooled prevalence of lesions considered
a successful target of surveillance according to the
CAPS deﬁnition was 3.3% (Figure 3), while the
actual pooled prevalence of ‘‘preneoplastic’’ target
lesions (advanced IPMNs and PanIN3 lesions) was
1.6% (see Supplementary Figure 1). The pooled esti-
mated rate of lesions considered a successful target of
surveillance during follow-up amounted to ﬁve cases
per 1000 pyrs, equal to an annual risk of 0.5%
(Figure 4).
EUS seemed able to diagnose more solid lesions and
MRI more cystic ones (Figure 5). Moreover, the rate of
lesions considered a successful target of surveillance
was much lower in FPC compared to HRI with speciﬁc
syndromes (Figure 6). This is not surprising as in FPC
the causal mutation is unknown despite a clear auto-
somal dominant inheritance pattern. Therefore, half of
FPC individuals undergo surveillance without carrying
the causal mutation.
Of the 1588 screened HRIs, 6.8% underwent sur-
gery, with histologically conﬁrmed lesions considered
a successful target of surveillance in 3.3%. To date,
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Figure 6. Pooled prevalence of lesions considered a successful target of surveillance in the different high-risk individual subgroups.
The pooled prevalence of lesions considered a successful target of surveillance diagnosed in familial pancreatic cancer (FPC) was 3%
(95% confidence interval (CI) 2%–5%) with moderate heterogeneity (I2¼ 22.2%). The pooled prevalence in familial atypical multi-mole
melanoma syndrome (FAMMM) was 5% (95% CI 3%–9%), in hereditary pancreatitis (HP) was 4% (CI 1%–14%), in hereditary breast-
ovarian cancer syndrome (HBOC) or BRCA1/BRCA2 or PALB2 mutation carriers was 6.3% (95% CI 3%–14%), and in Peutz-Jeghers
syndrome (PJS) it was 12.2% (95% CI 4%–32%). Notably, in all these genetic syndromes but HP, there was no heterogeneity (I2¼ 0%).
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there is little consensus about which lesions detected by
surveillance represent an indication for surgery,4 con-
sidering the morbidity of pancreatic surgery.27 It is
unknown whether for example in the case of BD-
IPMNs the same criteria for resection apply in HRIs
compared to sporadic cases.28 A recent study showed
that cystic lesions diagnosed in HRIs with a known
mutation are more prone to progress compared to
those discovered in FPC individuals, although this
latter group had a signiﬁcantly higher prevalence of
cystic lesions.29 There is also evidence of a high rate
of lymph node involvement and poor prognosis in
HRIs with PDAC even with very small lesions.9,18
This might justify a more aggressive attitude toward
resecting precursor lesions in this setting.
A proportion of patients diagnosed with PDAC
(n¼ 9, pooled prevalence 1%) were identiﬁed at an
advanced/metastatic stage. Two of them were prevalent
cases diagnosed at baseline. The other patients who
underwent surgical resection with positive resection
margins, or who were diagnosed with an unresectable
interval cancer during subsequent follow-up, however,
should be considered a failure of surveillance. The pro-
portion of unresectable PDAC was similar in people
with FPC, FAMMM, and HBOC. This raises concerns
about the validity of currently performed surveillance
programs.
In four cases the resected lesions were pNENs, only
one2 with diameter >1.5 cm. The European
Neuroendocrine Tumours Society guidelines30 would
not recommend surgery for incidentally detected
pNENs <2 cm.
Few studies compared the diagnostic yield
of EUS and MRI/magnetic resonance cholangiopan-
creatography. A high concordance between the two
methods was described by Canto et al.,6 while only a
55% agreement was shown by Harinck et al.7 for the
detection of clinically relevant lesions. In the present
study, the pooled prevalence of solid lesions detected
by EUS was higher compared to MRI (5.2% vs 4.1%),
while MRI had a higher yield for cystic lesions (22.4%
vs 16.6%). The pooled prevalence of lesions considered
a successful target of surveillance was similar for EUS
and MRI. A limitation of this analysis is the high het-
erogeneity between studies in terms of MRI protocols,
and the use of radial EUS in some studies, while linear
EUS is able to detect more pancreatic lesions in
HRIs.31 The two methods might be considered comple-
mentary rather than interchangeable in surveillance
programs,7 and their use should be tailored considering
local expertise.
The yield of surveillance programs in diﬀerent HRI
subgroups is another interesting subject. The pooled
prevalence of lesions considered a successful target of
surveillance in the present meta-analysis was 3% in
FPC individuals, representing the majority of people
screened, 4% in HP, 5% in FAMMM, 6.3% in
HBOC, BRCA1/2, or PALB2 mutations carriers, and
12.2% in PJS. Notably, while the results obtained in
FPC showed a certain heterogeneity, this was not the
case in patients with genetic syndromes. It would be
attractive to tailor surveillance in terms of age at
which to start, modality, and follow-up intervals
based on the frequency and growth characteristics of
the lesions diagnosed in each HRI subgroup.
Vasen et al.15 recently reported that IPMNs with
high-grade dysplasia and multifocal PanINs3 were
more frequent in FPC compared to FAMMM patients,
while the rate of diagnosed PDAC was higher in this
latter group. Further studies into the diﬀerential risk
and growth characteristics of the various subgroups
of HRIs are needed.
This is the ﬁrst study to systematically appraise the
available literature evidence from surveillance studies in
HRIs for developing PDAC. Although we developed a
priori hypotheses for sensitivity analyses considering
likely sources of heterogeneity, the observed heterogen-
eity between studies reﬂecting diﬀerences in surveillance
tests, intervals, type of reported lesions, and kind of
HRIs enrolled is a potential limitation. The lack of
individual patient data limited the possibility of per-
forming any analysis other than that of aggregate
data, and the inﬂuence of factors such as the age of
the individuals enrolled in the surveillance programs,
and the relevance of risk factors such as smoking,
could not be appropriately considered.
In conclusion, the pooled prevalence rate of resected
lesions that can be considered a successful target of
surveillance during PDAC surveillance programs in
HRIs is 3.3% with an annual risk of 0.5%. The
pooled prevalence rate of successful ‘‘premalignant’’
target lesions is, however, lower and equal to only
1.6%. A higher prevalence rate was observed in HRI
carriers with a speciﬁc DNA mutation compared to
HRIs with FPC in whom the mutation is unknown.
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Appendix 1
Search strategy
The following search strategy was employed:
(Neoplasm, Pancreatic OR Pancreatic Neoplasm
OR Neoplasms, Pancreas OR Pancreas Neoplasm OR
Neoplasms, Pancreatic OR Cancer of Pancreas OR
Pancreas Cancers OR Pancreas Cancer OR Cancer,
Pancreas OR Cancers, Pancreas OR Pancreatic
Cancer OR Cancer, Pancreatic OR Cancers,
Pancreatic OR Pancreatic Cancers OR Cancer of the
Pancreas) AND (Cancer Early Detection OR Cancer
Screening OR Screening, Cancer OR Cancer
Screening Tests OR Cancer Screening Test OR
Screening Test, Cancer OR Screening Tests, Cancer
OR Test, Cancer Screening OR Tests, Cancer
Screening OR Early Diagnosis of Cancer OR Cancer
Early Diagnosis) AND (High Risk OR High-Risk indi-
viduals OR High-Risk patients OR High-Risk cohort
OR High-Risk population OR FPC OR familial pan-
creatic cancer OR inherited pancreatic cancer OR
HBOC OR hereditary breast and ovarian cancer syn-
drome OR BRCA OR FAMMM OR familial atypical
multiple mole melanoma OR PJS OR Peutz-Jeghers
syndrome OR HNPCC OR hereditary nonpolyposis
colorectal cancer OR PALB OR mismatch repair
gene mutation OR Genetic Susceptibility OR Genetic
Susceptibilities OR Susceptibilities, Genetic OR
Susceptibility, Genetic OR Genetic Predisposition OR
Genetic Predispositions OR Predispositions, Genetic
OR Predisposition, Genetic).
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